CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 28 enrolled
Drug / intervention
Enzastaurin HCldrug
Likely dose
1200 mg loading dose orally, then 500 mg orally dailyAI-extracted
Key inclusion· 3
  • ✓Diagnosed with colorectal cancer that is advanced or metastatic (has spread to other parts of the body)
  • ✓Able to visit the doctor's office every 28 days for at least 6 months
  • ✓Able to swallow tablets
Key exclusion· 2
  • ✕Women cannot be pregnant or breastfeeding
  • ✕No history of significant heart disease or any other significant medical problems as determined by the participant's physician

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00192114
NCT00192114Phase 2Completed
CompareCT.gov

A Phase 2 Study of Oral Enzastaurin HCl in Patients With Metastatic Colorectal Cancer

Eli Lilly and Company·interventional·Posted Sep 19, 2005·Updated Aug 6, 2020

In Brief

A Phase 2 clinical trial evaluating Enzastaurin HCl for Colonic Neoplasms. Completed, enrolled 28 participants across 3 sites in 2 countries.

Detailed Summary

Enzastaurin given daily to participants with colorectal cancer who have Stage 4 disease and have not received prior chemotherapy for advanced colorectal cancer

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsColonic Neoplasms
CountriesDenmark, Sweden
Collaborators--

Timeline

Phase 2CompletedFinished
20052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedSep 19, 2005
Enrollment StartAug 1, 2005
Primary CompletionMar 1, 2008
TodayJul 2, 2026
Enrollment to primary: 2.6 yearsPosted 20.8 years ago

Interventions

Enzastaurin HCldrug

1200 milligrams (mg) loading dose orally, then 500 mg, orally, daily, up to six 28-day cycles.